- The approved drugs in the hereditary angioedema
space target complement proteins, androgen receptors, follicle-stimulating hormone, gonadotropin-releasing hormone, progesterone receptor, bradykinin B2 receptor, and the kinin-kallikrein system.
: a bradykinin-mediated swelling disorder.
A nationwide survey of hereditary angioedema
due to C1 inhibitor deficiency in Italy.
Ressel, "Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema
due to C1 esterase inhibitor deficiency," JAMA Internal Medicine, vol.
Cabanas, "Management of hereditary angioedema
in pregnant women: A review," International Journal of Women's Health, vol.
(HAE), caused by C1-INH deficiency, is a rare disease with an estimated frequency of 1:10.000-1:150.000 (11, 12).
Short analytical review: the pathophysiology of hereditary angioedema
. Clin Immunol 2005;114(1):3-9.
RUCONEST[R] (C1 Esterase Inhibitor [Recombinant]) 50 IU/kg is an injectable medicine that is used to treat acute angioedema attacks in adult and adolescent patients with hereditary angioedema
Icatibant for the treatment of hereditary angioedema
. Ann Pharmacother 2013;47(l):49-55.
Dr Bruno Giannetti, MD PhD, chief operations officer of Pharming, said, 'hereditary angioedema
patients in the US are currently facing a shortage of plasma-derived C1 inhibitor used to prevent attacks.
Pharmaceutical company Pharming Group NV (Euronext Amsterdam:PHARM) revealed on Monday that it has filed its supplemental Biologics License Application (BLA) with the US Food and Drug Administration (FDA) for RUCONEST for routine prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema